Oral bisphosphonate for postmenopausal osteoporosis.
Weekly oral treatment that can be administered immediately after food intake.
It slows down the cells which break down bone.
It is used to treat or prevent osteoporosis, and treat Paget’s disease of bone.
It is taken by mouth.
Trade names Actonel, Atelvia,
Pregnancy category AU: B3
Routes of administration By mouth
Bioavailability
0.63%
Protein binding
~24%
Metabolism None
Elimination half-life 1.5 h
Excretion
Kidney and fecal
Bisphosphonate Relative potency
Etidronate 1
Tiludronate 10
Pamidronate 100
Alendronate 100-500
Ibandronate 500-1000
Risedronate 1000
Zoledronate 5000
In common with other bisphosphonate drugs, risedronate appears to be associated with the rare side effect osteonecrosis of the jaw, often preceded by dental procedures inducing trauma to the bone.
A safe and effective drug in preventing bone mineral density loss in patients with both breast and prostate cancer.